Kelly RJ - Search Results

1

Axitinib (AG-013736).

Kelly RJ, Rixe O. Kelly RJ, et al. Recent Results Cancer Res. 2010;184:33-44. doi: 10.1007/978-3-642-01222-8_3. Recent Results Cancer Res. 2010. PMID: 20072829 Review.

2

Renal toxicity of targeted therapies.

Kelly RJ, Billemont B, Rixe O. Kelly RJ, et al. Target Oncol. 2009 Apr;4(2):121-33. doi: 10.1007/s11523-009-0109-x. Epub 2009 May 6. Target Oncol. 2009. PMID: 19421832 Review.

3

Metastatic phyllodes tumor causing small-bowel obstruction.

Kelly RJ, Barrett C, Swan N, McDermott R. Kelly RJ, et al. Clin Breast Cancer. 2009 Aug;9(3):193-5. doi: 10.3816/CBC.2009.n.033. Clin Breast Cancer. 2009. PMID: 19661046

4

Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.

Kelly RJ, Rixe O. Kelly RJ, et al. Target Oncol. 2009 Dec;4(4):297-305. doi: 10.1007/s11523-009-0126-9. Epub 2009 Oct 30. Target Oncol. 2009. PMID: 19876699

5

Transforming growth factor-beta: a target for cancer therapy.

Kelly RJ, Morris JC. Kelly RJ, et al. J Immunotoxicol. 2010 Mar;7(1):15-26. doi: 10.3109/15476910903389920. J Immunotoxicol. 2010. PMID: 19916703 Review.

6

Small-molecule inhibitors of the human epidermal receptor family.

Carter CA, Kelly RJ, Giaccone G. Carter CA, et al. Among authors: kelly rj. Expert Opin Investig Drugs. 2009 Dec;18(12):1829-42. doi: 10.1517/13543780903373343. Expert Opin Investig Drugs. 2009. PMID: 19938898 Review.

7

Antiangiogenesis induced tumor cavitation in lung cancer.

Kelly RJ, Hnatiuk O, Giaccone G. Kelly RJ, et al. J Thorac Oncol. 2009 Dec;4(12):1573-5. doi: 10.1097/JTO.0b013e3181c09fc2. J Thorac Oncol. 2009. PMID: 20009913 No abstract available.

8

Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.

Kelly RJ, Gulley JL, Giaccone G. Kelly RJ, et al. Clin Lung Cancer. 2010 Jul 1;11(4):228-37. doi: 10.3816/CLC.2010.n.029. Clin Lung Cancer. 2010. PMID: 20630824 Free PMC article. Review.

9

The role of talactoferrin alpha in the treatment of non-small cell lung cancer.

Kelly RJ, Giaccone G. Kelly RJ, et al. Expert Opin Biol Ther. 2010 Sep;10(9):1379-86. doi: 10.1517/14712598.2010.512914. Expert Opin Biol Ther. 2010. PMID: 20684737 Free PMC article. Review.

10

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Hassan R, et al. Among authors: kelly rj. Clin Cancer Res. 2010 Dec 15;16(24):6132-8. doi: 10.1158/1078-0432.CCR-10-2275. Epub 2010 Oct 29. Clin Cancer Res. 2010. PMID: 21037025 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results